In a phase II trial of a whole-cell lysate dendritic cell vaccine combined with standard therapy for newly diagnosed glioblastoma, patients with a low PD-1+/CD8+ ratio in tumor tissue had a median overall survival of 61 versus 20.7 months for patients with a high PD-1+/CD8+ ratio (232). This evidence concerns the gene PDCD1 and glioblastoma.